Literature DB >> 31784742

Salinomycin targets the genome of radioresistant cells in glioblastomas.

Steven L Carroll1, Jody Fromm Longo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31784742      PMCID： PMC7032623          DOI： 10.1093/neuonc/noz224

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  11 in total

1.  Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.

Authors:  Carlos Rodrigo Gil Del Alcazar; Pavlina Krasimirova Todorova; Amyn A Habib; Bipasha Mukherjee; Sandeep Burma
Journal:  Mol Cancer Res       Date:  2016-06-29       Impact factor: 5.852

Review 2.  Salinomycin and its derivatives - A new class of multiple-targeted "magic bullets".

Authors:  Michał Antoszczak; Adam Huczyński
Journal:  Eur J Med Chem       Date:  2019-05-09       Impact factor: 6.514

3.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

Review 4.  DNA repair targeted therapy: The past or future of cancer treatment?

Authors:  Navnath S Gavande; Pamela S VanderVere-Carozza; Hilary D Hinshaw; Shadia I Jalal; Catherine R Sears; Katherine S Pawelczak; John J Turchi
Journal:  Pharmacol Ther       Date:  2016-02-16       Impact factor: 12.310

5.  Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.

Authors:  Shigeo Ohba; Joydeep Mukherjee; Wendy L See; Russell O Pieper
Journal:  Cancer Res       Date:  2014-07-17       Impact factor: 12.701

6.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

7.  Salinomycin inhibits the tumor growth of glioma stem cells by selectively suppressing glioma-initiating cells.

Authors:  Tunan Chen; Liang Yi; Fei Li; Rong Hu; Shengli Hu; Yi Yin; Chuan Lan; Zhao Li; Chuhua Fu; Liu Cao; Zhi Chen; Jishu Xian; Hua Feng
Journal:  Mol Med Rep       Date:  2014-12-01       Impact factor: 2.952

8.  Salinomycin potentiates the cytotoxic effects of TRAIL on glioblastoma cell lines.

Authors:  Alessia Calzolari; Ernestina Saulle; Maria Laura De Angelis; Luca Pasquini; Alessandra Boe; Federica Pelacchi; Lucia Ricci-Vitiani; Marta Baiocchi; Ugo Testa
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

9.  Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.

Authors:  Theo A Knijnenburg; Linghua Wang; Michael T Zimmermann; Nyasha Chambwe; Galen F Gao; Andrew D Cherniack; Huihui Fan; Hui Shen; Gregory P Way; Casey S Greene; Yuexin Liu; Rehan Akbani; Bin Feng; Lawrence A Donehower; Chase Miller; Yang Shen; Mostafa Karimi; Haoran Chen; Pora Kim; Peilin Jia; Eve Shinbrot; Shaojun Zhang; Jianfang Liu; Hai Hu; Matthew H Bailey; Christina Yau; Denise Wolf; Zhongming Zhao; John N Weinstein; Lei Li; Li Ding; Gordon B Mills; Peter W Laird; David A Wheeler; Ilya Shmulevich; Raymond J Monnat; Yonghong Xiao; Chen Wang
Journal:  Cell Rep       Date:  2018-04-03       Impact factor: 9.423

10.  Simultaneous targeting of DNA replication and homologous recombination in glioblastoma with a polyether ionophore.

Authors:  Yi Chieh Lim; Kathleen S Ensbey; Carolin Offenhäuser; Rochelle C J D'souza; Jason K Cullen; Brett W Stringer; Hazel Quek; Zara C Bruce; Amanda Kijas; Valentina Cianfanelli; Bijan Mahboubi; Fiona Smith; Rosalind L Jeffree; Lisa Wiesmüeller; Adrian P Wiegmans; Amanda Bain; Fanny J Lombard; Tara L Roberts; Kum Kum Khanna; Martin F Lavin; Baek Kim; Petra Hamerlik; Terrance G Johns; Mark J Coster; Andrew W Boyd; Bryan W Day
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300
View more
  1 in total

Review 1.  Salinomycin as a potent anticancer stem cell agent: State of the art and future directions.

Authors:  Dan Qi; Yunyi Liu; Juan Li; Jason H Huang; Xiaoxiao Hu; Erxi Wu
Journal:  Med Res Rev       Date:  2021-11-16       Impact factor: 12.388
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.